INRAE, Evolugate Enter Option License Agreement to Advance Probiotics to Manage Human Cholesterol

INRAE, Evolugate Enter Option License Agreement to Advance probiotics to manage human cholesterol (Paris, May 27, 2020) INRAE, is pleased to announce that it has entered into an exclusive option license agreement with biotechnology company Evolugate of Gainesville, FL to optimize its probiotic to manage human hypercholesterolemia, a major risk factor for cardiovascular diseases. INRAE … Continue reading INRAE, Evolugate Enter Option License Agreement to Advance Probiotics to Manage Human Cholesterol